Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

por Van Cutsem, E, Yoshino, T, Lenz, H J, Lonardi, S, Falcone, A, Limón, M L, Saunders, M, Sobrero, A, Park, Y S, Ferreiro, R, Hong, Y S, Tomasek, J, Taniguchi, H, Ciardiello, F, Stoehr, J, Oum’Hamed, Z, Vlassak, S, Studeny, M, Argiles, G
Publicado 2018